Raymond James Financial’s Virtus Biotech ETF BBP Stock Holding History

Raymond James Financial’s Portfolio BBP Stock Details BBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98M	Buy	20,606 +3,302	+19%	+$287K	﹤0.01%	3488
2026 Q1	$1.44M	Buy	17,304 +11,061	+177%	+$909K	﹤0.01%	3597
2025 Q4	$499K	Sell	6,243 -275	-4%	-$20.9K	﹤0.01%	4267
2025 Q3	$456K	Sell	6,518 -10,915	-63%	-$715K	﹤0.01%	4169
2025 Q2	$1.02M	Sell	17,433 -7,359	-30%	-$416K	﹤0.01%	3580
2025 Q1	$1.45M	Buy	24,792 +16,866	+213%	+$1.03M	﹤0.01%	3215
2024 Q4	$476K	Buy	+7,926	New	+$501K	﹤0.01%	3942

Other funds holding BBP

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WBI Investments Red Bank, New Jersey $403M AUM 42.23% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $10.3B AUM 25.54% 1-Year Est. Return

Raymond James Financial's BBP Position: Q2 2026 in Review

Raymond James Financial increased its Virtus Biotech ETF (BBP) stake by 19% in Q2 2026, buying an estimated $287K and bringing the position to 20,606 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

Raymond James Financial first reported a position in BBP in Q4 2024 and has held it in 7 quarters since. 25 funds tracked by Wall St. Rank hold BBP as of Q2 2026.

Raymond James Financial held 20,606 shares of Virtus Biotech ETF worth $1.98M as of Q2 2026.
Raymond James Financial bought 3,302 Virtus Biotech ETF shares in Q2 2026, an estimated $287K.
Virtus Biotech ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3488 holding.
Raymond James Financial first reported a position in Virtus Biotech ETF in Q4 2024 and has held it in 7 quarters since.
25 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.